ILA Island Pharmaceuticals Limited
Healthcare · Biotechnology
· website
$0.41
52wk 0.17 – 0.63
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Island Pharmaceuticals Limited
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$122.81M
P/E (trailing)
—
P/E (forward)
-8.83
EPS (trailing)
-0.03
Dividend yield
—
Payout ratio
0.0%
Beta
0.11
EV / EBITDA
—
Price / Book
15.37
ROE
-130.3%
Operating margin
-12,053.0%
Net margin
0.0%
Total cash
$6.87M
Total debt
$0
Current ratio
8.40
Debt / Equity
—
Free cash flow
$-2.35M
Avg volume
354,063
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.02
- Free cash flow—
- Net debt—